Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 26,063 | 25,881 | 20,401 | 12,043 | 3,695 |
| Cost of Goods | 1,238 | 12,379 | 1,345 | 1,366 | 2,303 |
| Gross Profit | 24,825 | 13,502 | 19,056 | 10,677 | 1,392 |
| Operating Expenses | 20,920 | 84,920 | 24,763 | 26,459 | 29,001 |
| Operating Income | 4,143 | -71,039 | -5,362 | -15,416 | -27,306 |
| Interest Expense | 2,051 | 2,009 | 1,969 | 2,194 | 2,312 |
| Other Income | -3,069 | 149,954 | 5,414 | -2,758 | -3,607 |
| Pre-tax Income | -977 | 76,906 | -1,917 | -20,368 | -33,225 |
| Income Tax | -433 | 2,199 | 1,182 | 15,371 | N/A |
| Net Income Continuous | -544 | 74,707 | -3,099 | -35,739 | -33,225 |
| Net Income | $-544 | $74,707 | $-3,099 | $-35,739 | $-33,225 |
| EPS Basic Total Ops | -0.01 | 1.24 | -0.06 | -0.71 | -0.69 |
| EPS Basic Continuous Ops | -0.01 | 1.36 | -0.06 | -0.71 | -0.70 |
| EPS Diluted Total Ops | -0.01 | 1.21 | -0.06 | -0.71 | -0.69 |
| EPS Diluted Continuous Ops | -0.01 | 1.33 | -0.06 | -0.71 | -0.70 |
| EPS Diluted Before Non-Recurring Items | -0.01 | -0.06 | -0.06 | -0.67 | -0.69 |
| EBITDA(a) | $3,324 | $-11,433 | $-4,018 | $-14,658 | $-25,689 |